Skip to main content
Perspective
Prescription Drug Provisions in the Inflation Reduction Act of 2022: A Payer Perspective
Read More
FDA Updates
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Jerm Day-Storms, PhD, MWC
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Read More
SABCS 2023 HR+/HER2-
Rapid Reactions, Breast Cancer
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
Read More
FDA Updates
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Read More
FDA Updates
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Read More
Breast Cancer
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
Read More
Symptom Management Overview, Adverse Events, Infusion Issues
Management of Iron Infusion Reactions
Raluca Laza, PharmD; Meredith Keisler, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Andrea Dickens, PharmD, BCOP
Read More
Page 26 of 199
Results 251 - 260 of 1986